Results 51 to 60 of about 35,652 (265)

Promising Lead Compounds in the Development of Potential Clinical Drug Candidate for Drug-Resistant Tuberculosis

Molecules, 2020
According to WHO report, globally about 10 million active tuberculosis cases, resulting in about 1.6 million deaths, further aggravated by drug-resistant tuberculosis and/or comorbidities with HIV and diabetes are present. Incomplete therapeutic regimen,
Saad Alghamdi, Shaheed Ur Rehman, Nashwa Talaat Shesha, Hani Faidah, Muhammad Khurram, Sabi Ur Rehman   +5 more
doaj   +1 more source

Influence of drug/lipid interaction on the entrapment efficiency of isoniazid in liposomes for antitubercular therapy: a multi-faced investigation [PDF]

arXiv, 2021
Hypothesis. Isoniazid is one of the primary drugs used in tuberculosis treatment. Isoniazid encapsulation in liposomal vesicles can improve drug therapeutic index and minimize toxic and side effects. In this work, we consider mixtures of hydrogenated soy phosphatidylcholine/phosphatidylglycerol (HSPC/DPPG) to get novel biocompatible liposomes for ...
arxiv  

Tuberculosis-associated anemia is linked to a distinct inflammatory profile that persists after initiation of antitubercular therapy

Scientific Reports, 2019
Pulmonary tuberculosis (PTB) is associated with chronic inflammation and anemia. How anemia impacts systemic inflammation in PTB patients undergoing antitubercular therapy (ATT) is not fully understood.
Leonardo Gil-Santana, Luís A. B. Cruz, M. Arriaga, P. Miranda, K. Fukutani, P. S. Silveira-Mattos, Elisangela C Silva, Marina G. Oliveira, Eliene Mesquita, Anneloek Rauwerdink, F. Cobelens, Martha M. Oliveira, A. Kritski, B. Andrade   +13 more
semanticscholar   +1 more source

When you never thought it would be me

APIK Journal of Internal Medicine, 2020
Tuberculosis, both pulmonary and extrapulmonary, is a procoagulant state, which can lead to deep-vein thrombosis and thromboembolism. Rifampicin, the antitubercular drug by itself, can cause a procoagulant state.
K R Raveendra, H Sivaranjani, Shivakumar Hrishikesh   +2 more
doaj   +1 more source

Isoniazid‐Dihydropyrimidinone Molecular Hybrids: Design, Synthesis, Antitubercular Activity, and Cytotoxicity Investigations with Computational Validation

ChemMedChem, EarlyView.
Antitubercular evaluation of a novel library of isoniazid‐dihydropyrimidinone molecular hybrids (8a–8n) discloses a potent compound with MIC = 0.39μg mL−1 against M. tuberculosis mc26230. Cytotoxicity, stability, and in silico studies, including molecular docking and ADME/T (absorption, distribution, metabolism, excretion, and toxicity) analysis ...
Gobind Kumar, Pule Seboletswe, Sahil Mishra, Neha Manhas, Safiyah Ghumran, Nagaraju Kerru, Françoise Roquet‐Banères, Maëlle Foubert, Laurent Kremer, Gaurav Bhargava, Parvesh Singh   +10 more
wiley   +1 more source

Novel quinazolinones active against multidrug‐resistant Mycobacterium tuberculosis: synthesis, antimicrobial evaluation and in silico exploration of PonA1 as a potential target

ChemMedChem, Accepted Article.
Quinazolinone derivatives have emerged as promising scaffolds in antimicrobial drug discovery. This work focuses on the design, synthesis, and evaluation of novel quinazolinone‐based compounds and predicts their potential to interact with mycobacterial penicillin‐binding proteins (PBPs).
MAREK KERDA, Daria Nawrot, Petr Slechta, Mirek Domanský, Asal Askari, Hanieh Kamangar, Ondřej Janďourek, Klára Konečná, Pavla Paterová, Ingrid Hlbočanová, Miloslav Macháček, Matteo Mori, Fiorella Meneghetti, Martin Doležal, Jan Zitko, Ghada Bouz   +15 more
wiley   +1 more source

Erythema multiforme due to antitubercular drugs

Lung India, 2011
Sameer Gulati, HP Paljor, Rohit Mahajan, Pankaj Goel   +3 more
openalex   +5 more sources

V. On the Antitubercular Action of Iodoform [PDF]

Annals of Surgery, 1887
n ...
openaire   +3 more sources

Dual Antitubercular and Antileishmanial Profiles of Quinoxaline Di-N-Oxides Containing an Amino Acidic Side Chain

Pharmaceuticals
We present a new category of quinoxaline di-N-oxides (QdNOs) containing amino acid side chains with dual antituberculosis and antileishmanial activity.
Juan F. González, María-Auxiliadora Dea-Ayuela, Lena Huck, José María Orduña, Francisco Bolás-Fernández, Elena de la Cuesta, Nazia Haseen, Ashraf Ali Mohammed, J. Carlos Menéndez   +8 more
doaj   +1 more source

Mycobacterium tuberculosis Molecular Determinants of Infection, Survival Strategies, and Vulnerable Targets

Pathogens, 2018
Mycobacterium tuberculosis is the causative agent of tuberculosis, an ancient disease which, still today, represents a major threat for the world population. Despite the advances in medicine and the development of effective antitubercular drugs, the cure
Davide M. Ferraris, Riccardo Miggiano, Franca Rossi, Menico Rizzi   +3 more
doaj   +1 more source